- About Us
- Services & Solutions
- Investor Relations
- News & Resources
Offering End-to-End Solutions
January 4, 2024
WuXi XDC Cayman Inc.(“WuXi XDC”, or the “Company”, stock code: 2268.HK ), a leading global Contract Research, Development and Manufacturing Organization (“CRDMO”) focused on antibody drug conjugates (“ADC”) and broader bioconjugate market, today announced that members of the Company’s senior management team will participate in 42nd Annual J.P. Morgan Healthcare Conference. Dr. Jimmy Li, CEO of WuXi XDC, will deliver a keynote speech.
Global Premier Bioconjugation CRDMO to Enable and Expedite Innovations
Dr. Jimmy Li, CEO of WuXi XDC
China Standard Time (CST):
January 10, 2024 Wednesday 3:30AM
Pacific Standard Time (PST):
January 9, 2024 Tuesday 11:30AM
Through the direct link or the QR code, you will be able to participate in live broadcast of WuXi XDC’s keynote presentation session.
An archived replay will be available for up to 30 days following the completion of the event on the Investor Relations page of WuXi XDC’s website at:
Dr. Jimmy Li is CEO of WuXi XDC and is responsible for the overall strategic planning, business development and daily operations. Dr. Li has over 20 years of experience in biologics research, development, and cGMP manufacturing. With his leadership, WuXi XDC has become premier CRDMO focused on ADC and other bioconjugates market, providing over 300 global clients with an integrated technology and one-stop service platform that extends from discovery, development, manufacturing, and quality controls to regulatory filings. For two consecutive years, WuXi XDC has been recognized by the global industry and clients in the most influential “World ADC Awards” in the ADC field, winning “Best CDMO Winner” in 2023 and “Best CMO Runner-up” in 2022.
In Nov 2023, WuXi XDC successfully listed on the Main Board of Hong Kong Stock Exchange. In terms of the total number of integrated CMC projects, WuXi XDC is the largest bioconjugate CRDMO globally as of the end of 2022.
Dr. Li joined the WuXi Biologics Group in 2011. Throughout 2021 and 2022, Dr. Li spearheaded the integration of the ADC capabilities into WuXi XDC and accumulatively his team had completed more than 40 ADCs and other bioconjugates IND filings in China, US and Europe. During his tenure at MFG1, Dr. Li led the efforts to successfully pass the company’s first FDA and EMA pre-license inspections and achieved the first FDA biologics BLA approval in China.
Dr. Li holds B.S. degree from Tsinghua University, and Ph.D. degree from University of Maryland Baltimore County, majoring in Chemical and Biochemical Engineering.
About WuXi XDC
WuXi XDC Cayman Inc.(“WuXi XDC” or the “Company”, stock code: 2268.HK) is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody intermediates and other biologics intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products. For more information about WuXi XDC, please visit: www.wuxixdc.com